Gemfibrozil

Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

Product Specifications

CAS Number

[25812-30-0]

Product Name Alternative

CI-719

UNSPSC

12352005

Hazard Statement

H302

Target

Cytochrome P450; PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Metabolic Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Gemfibrozil.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C(C)(C)CCCOC1=CC(C)=CC=C1C

Molecular Formula

C15H22O3

Molecular Weight

250.34

Precautions

H302

References & Citations

[1]Pahan K, et al. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277 (48) :45984-91. Epub 2002 Sep 18.|[2]Almad A, et al. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011 Dec;232 (2) :309-17.|[3]Wang JS, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30 (12) :1352-6.